1-877-327-4636 Alcohol and Substance
1-800-436-8477 Morning Sickness
1-888-246-5840 HIV and HIV Treatment
1-877-439-2744 Motherisk Helpline
416-813-6780 Motherisk Helpline
Pregnancy & Breastfeeding Resources
Motherisk Update 2014
Fetal Alcohol Canadian Expertise (FACE) Satellite Meeting,
Details to be announced
- Read more in our News Archive
Current Studies at Motherisk
Neurodevelopment of Children Exposed in-Utero to Chemotherapy for Maternal Breast Cancer (Dr. I Nulman)
Diclegis Surveillance Program Study
Diclectin Surveillance Program Study
Study seeks women between 4 and 12 weeks in their pregnancy with morning sickness (NVP)
Pregnancy in Women with Multiple Sclerosis
Environmental Exposures and Children's Health
Alcohol Use during Pregnancy
Control of Hypertension in Pregnancy Study
Folic Acid Before and During Pregnancy
Lamisil in Pregnancy
Meridia in Pregnancy
Autoimmune Diseases in Pregnancy Project
The Cancer in Pregnancy ForumArchived Questions and Answers
This Forum has been the centre of an exceptional exchange of knowledge diagnosis, treatment, symptoms and other effects of cancer during pregnancy and lactation. All are welcome to review the Questions and Answers posted here, provided that they acknowledge and accept the important proviso and disclaimer below.
Dear colleages, I write you requiring a consultation about the cytotoxic treatment during pregnancy. Our patient underwent surgical treatment for the breast cancer. Lymphatic nodes were positive for metastasis, therefore chemotherapy with doxorubicin, cyclophosphamid, and docetaxel is planed on 20week of her pregnancy.
We suppose there is relatively low risk for great malformations, but we cannot exclude IUGR, miscarriege,panmyelopenia, functional changes including mental retardation, infertility and cancer in adult of exposed child What are you recommending for this case. How high risk can be estimated for her pregnancy?
Thank you for your help.
Based on the information you have provided we would suggest that the risk of malformation in the 20th week of pregnancy is not greater than the risk in healthy women. The risk of IUGR and miscarriage is substantial and the woman needs close followup-however this should not preclude the administration of chemotherapy.
The delivery should be planned for the time that the fetus will not be at risk of pancytopenia. There are no long term known risks for second malignancies,infertility or neurological maldevelopment.
A word of caution: there is a relatively small amount of data re taxanes in pregnancy.